CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
oleh: Gerard M. Walls, Jamie B. Oughton, Anthony J. Chalmers, Sarah Brown, Fiona Collinson, Martin D. Forster, Kevin N. Franks, Alexandra Gilbert, Gerard G. Hanna, Nicola Hannaway, Stephen Harrow, Tom Haswell, Crispin T. Hiley, Samantha Hinsley, Matthew Krebs, Geraldine Murden, Rachel Phillip, Anderson J. Ryan, Ahmed Salem, David Sebag-Montefoire, Paul Shaw, Chris J. Twelves, Katrina Walker, Robin J. Young, Corinne Faivre-Finn, Alastair Greystoke
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2020-11-01 |
Deskripsi
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.